Breast Cancer Update: Surgical Edition, Issue 1, 2019


Interview with Charles E Geyer Jr, MD

Track 1: Case: A premenopausal woman in her mid-40s with Grade II, ER/PR-positive, HER2-negative lobular breast cancer, a 21-gene assay Recurrence Score (RS) of 10 and a deleterious CHEK2 mutation undergoes a bilateral mastectomy
Track 2: Impact of gene-expression assay results on therapeutic decision-making
Track 3: Results of the Phase III TAILORx trial evaluating chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative breast cancer and an intermediate RS
Track 4: Clinical utility of the 21-gene and 70-gene assays
Track 5: Benefit with the addition of ovarian function suppression to endocrine therapy for premenopausal women with ER-positive breast cancer at high risk for recurrence
Track 6: Approach to assessing the adequacy of ovarian function suppression in premenopausal patients receiving aromatase inhibition
Track 7: Significance of clinical risk category in prognosis and in the prediction of chemotherapy benefit by age and RS in the TAILORx trial
Track 8: Use of adjuvant bone-modifying agents to reduce the risk of aromatase inhibitor-associated bone loss and fracture
Track 9: Role of the 21-gene assay RS in guiding neoadjuvant therapy decision-making for ER-positive, HER2-negative localized breast cancer
Track 10: Mechanism of action, efficacy and tolerability of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer
Track 11: Investigation of CDK4/6 inhibitors alone or in combination with endocrine therapy in the neoadjuvant and adjuvant settings
Track 12: Case: A postmenopausal woman in her mid-50s with Grade I, ER-positive, PR-negative, HER2-negative infiltrating ductal carcinoma (IDC) with 1 positive node and a RS of 20 receives an aromatase inhibitor and denosumab
Track 13: Approach to the selection of adjuvant endocrine therapy; management of aromatase inhibitor-associated arthralgias
Track 14: Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
Track 15: Prospective data with and ongoing evaluation of the 21-gene and 70-gene assays for patients with node-positive disease
Track 16: Results from the Phase III KATHERINE study evaluating adjuvant T-DM1 versus trastuzumab for patients with HER2-positive localized breast cancer and residual disease after neoadjuvant treatment
Track 17: Rationale for the design and entry criteria of the KATHERINE study
Track 18: Mechanism of action, activity and tolerability of antibody-drug conjugates
Track 19: Second opinion: Therapeutic options for a patient in her mid-40s with recurrent, locally advanced, ER/PR-positive, HER2-positive breast cancer
Track 20: Clinical implications of the KATHERINE trial results

Interview with Tari A King, MD

Track 1: Recent developments in the surgical care of patients with breast cancer
Track 2: Predictive versus prognostic role of the 21-gene assay RS in ER-positive, HER2-negative, node-positive breast cancer
Track 3: Clinical implications of the TAILORx trial results
Track 4: Reliability of the 21-gene assay RS in guiding neoadjuvant therapy decision-making
Track 5: Impact of genomic assay testing and clinical features on the use of chemotherapy after the implementation of standardized reflex testing criteria
Track 6: Clinical utility of the 21-gene assay RS in the selection of therapy
Track 7: Application and utility of the MINDACT trial results; use of the 70-gene signature assay in breast cancer
Track 8: Criteria for surgeon-initiated reflex gene-expression profile testing for patients with early-stage breast cancer to reduce delays in the initiation of chemotherapy
Track 9: Surgeon variability and factors predicting the need for reoperation after breast-conserving surgery
Track 10: Recent trends in reoperation after initial lumpectomy for patients with breast cancer
Track 11: Multidisciplinary management of the axilla for patients with breast cancer undergoing primary mastectomy
Track 12: Optimal locoregional management of sentinel node-negative and node-positive breast cancer
Track 13: Key issues regarding gross and microscopic evaluation of breast and lymph node specimens after neoadjuvant systemic therapy
Track 14: Importance of accurate specimen evaluation in assessing treatment response
Track 15: Factors predicting the use of preoperative therapy for young women with breast cancer; impact on breast-conserving surgery
Track 16: Updated AJCC Staging Manual: Incorporation of tumor biology into breast cancer staging to tailor treatment and refine prognosis
Track 17: Case: A woman in her mid-40s with ER/PR-negative, HER2-positive IDC receives neoadjuvant paclitaxel/trastuzumab/pertuzumab on the Phase I DAPHNe trial
Track 18: Perspective on the results of the KATHERINE trial
Track 19: Threshold for neoadjuvant therapy in triple-negative versus HER2-positive breast cancer; side-effect profile of paclitaxel in combination with trastuzumab and pertuzumab
Track 20: Case: A woman in her mid-30s with triple-negative breast cancer has residual invasive disease in the breast and axillary lymph nodes after receiving neoadjuvant dose-dense AC followed by paclitaxel
Track 21: Perspective on the importance of genomic testing in guiding treatment decision-making for patients with newly diagnosed disease
Track 22: Surgical treatment options for patients with triple-negative breast cancer and germline BRCA mutations
Track 23: Case: A woman in her mid-40s with ER/PR-positive, HER2-negative IDC receives a RS of 18
Track 24: Effects of age, menopausal status and RS on the prediction of benefit from chemotherapy
Charles E Geyer Jr, MD
Professor of Medicine
Virginia Commonwealth
University School of Medicine
Harrigan, Haw
Luck Families Chair in Cancer Research
Associate Director of
Clinical Research
Massey Cancer Center
Richmond, Virginia
Tari A King, MD
Associate Chair for
Multidisciplinary Oncology
Department of Surgery
Division of Breast Surgery
Brigham and Women’s Hospital
Dana-Farber/Brigham and
Women’s Cancer Center
Anne E Dyson
Associate Professor of Surgery
Harvard Medical School
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida